Nanoparticles for cancer therapy using magnetic forces

Nanomedicine

Volumn 7, Issue 3, 2012, Pages 447-457

  Tietze, Rainer ^a   Lyer, Stefan ^a   Dürr, Stephan ^a   Alexiou, Christoph ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

cancer therapy; chemotherapy; drug delivery; iron oxide nanoparticles; magnetic drug targeting

Indexed keywords

CAMPTOTHECIN; CYTOSTATIC AGENT; DOXORUBICIN; EPIRUBICIN; FERUCARBOTRAN; MAGNETIC NANOPARTICLE; METHOTREXATE; MITOXANTRONE; NANOPARTICLE; OLEIC ACID; OXAMIC ACID; PHOSPHATIDYLCHOLINE; QUANTUM DOT; SUCCINIC ACID; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TIOPRONIN; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG TARGETING; HYPERTHERMIA; IMAGING SYSTEM; NANOMEDICINE; NANOTECHNOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FERRIC COMPOUNDS; HUMANS; HYPERTHERMIA, INDUCED; MAGNETS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 84857860947     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.10     Document Type: Review

References (82)

1. Von Stengel S, Kemmler W, Kalender WA, Engelke K, Lauber D. Differential effects of strength versus power training on bone mineral density in postmenopausal women: A 2-year longitudinal study. Br. J. Sports Med. 41(10), 649-655; discussion 655 (2007).
2. Husman G, Kaatsch P, Katalinic A et al. Krebs in Deutschland (Volume 7). Robert Koch-Institut, Berlin, Germany (2010).
3. Blair JA, Rauh D, Kung C et al. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat. Chem. Biol. 3(4), 229-238 (2007).
4. Gridelli C, Maione P, Bareschino MA et al. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res. 30(4), 1301-1310 (2010).
5. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 24(10), 1211-1217 (2006).
6. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007).
7. Bilkenroth U, Taubert H, Riemann D, Rebmann U, Heynemann H, Meye A. Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. Int. J. Cancer 92(4), 577-582 (2001).
8. Taupitz M, Wagner S, Hamm B, Dienemann D, Lawaczeck R, Wolf KJ. MR lymphography using iron oxide particles. Detection of lymph node metastases in the VX2 rabbit tumour model. Acta Radiol. 34, 10-15 (1993).
9. Harisinghani MG, Barentsz J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348(25), 2491-2499 (2003).
10. Gao Y. Biofunctionalization of magnetic nanoparticles. In:Biofunctionalization of Nanomaterials . Kumar CSSR (Ed.). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 72-89 (2005).
11. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 17(1), 31-48 (1995).
12. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47(1), 3-19 (2001).
13. Alksne JF, Fingerhut FA, Rand RW. Magnetically controlled metallic thrombosis of intracranial aneurysms. Surgery 60, 212-218 (1965).
14. Widder KJ, Morris RM, Poore GA, Howard DP, Senyei AE. Selective targeting of magnetic albumin microspheres to the yoshida sarcoma: ultrastructural evalutation of microsphere distribution. Eur. J. Cancer. Clin. Oncol. 19, 141-147 (1993).
15. Wilson MW, Kerlan RK Jr, Fidelman NA et al. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite - initial experience with four patients. Radiology 230(1), 287-293 (2004).
16. Lübbe AS, Bergemann C, Riess H et al. Clinical experiences with magnetic drag targeting: A Phase I study with 4-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 56(20), 4686-4693 (1996).
17. Alexiou C, Jurgons R, Schmid RJ et al. Magnetic drug targeting - biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J. Drug Target. 11(3), 139-149 (2003).
18. Alexiou C, Diehl D, Henninger P et al. A high field gradient magnet for magnetic drug targeting. IEEE Transact. Applied Superconduct. 16(2), 1527-1530 (2006).
19. Brigger I, Morizet J, Laudani L et al. Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J. Control. Release 100(1), 29-40 (2004).
20. Amstad E, Fischer H, Gehring AU, Textor M, Reimhult E. Magnetic decoupling of surface Fe3+ in magnetite nanoparticles upon nitrocatechol- anchored dispersant binding. Chem. Eur. J. 17(27), 7396-7398 (2011).
21. Lübbe AS, Bergemann C, Huhnt W et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 56(20), 4694-4701 (1996).
22. Kumar A, Jena PK, Behera S, Lockey RF, Mohapatra S. Multifunctional magnetic nanoparticles for targeted delivery. Nanomedicine 6(1), 64-69 (2010).
23. Perkins WR, Ahmad I, Li X et al. Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds. Int. J. Pharm. 200(1), 27-39 (2000).
24. Pankhurst QA, Thanh NKT, Jones SK, Dobson J. Progress in applications of magnetic nanoparticles in biomedicine. J. Physics D Appl. Physics 42(22), 224001 (2009).
25. Seliger C, Jurgons R, Wiekhorst F et al. In vitro investigation of the behaviour of magnetic particles by a circulating artery model. J. Magn. Magn. Mater. 311(1), 358-362 (2007).
26. Alexiou C, Jurgons R, Schmid R et al. [Magnetic drug targeting - a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies]. HNO 53(7), 618-622 (2005).
27. Alexiou C, Arnold W, Hulin P et al. Magnetic mitoxantrone nanoparticle detection by histology, x-ray and MRI after magnetic tumor targeting. J. Magn. Magn. Mater. 225(1-2), 187-193 (2001).
28. Rahn H, Gomez-Morilla I, Jurgons R, Alexiou C, Odenbach S. Microcomputed tomography analysis of ferrofluids used for cancer treatment. J. Phys. Condens. Matter 20(20), 204152-204156 (2008).
29. Wiekhorst F, Seliger C, Jurgons R et al. Quantification of magnetic nanoparticles by magnetorelaxometry and comparison to histology after magnetic drug targeting. J. Nanosci. Nanotechnol. 6(9-10), 3222-3225 (2006).
30. Tietze R. Quantification of drug-loaded magnetic nanoparticles in rabbit liver and tumor after in vivo administration. J. Magn. Magn. Mater. 321, 1465-1468 (2009).
31. Alexiou C, Jurgons R, Seliger C, Brunke O, Iro H, Odenbach S. Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting. Anticancer Res. 27(4A), 2019-2022 (2007).
32. Tietze R, Rahn H, Lyer S et al. Visualization of superparamagnetic nanoparticles in vascular tissue using XμCT and histology. Histochem. Cell Biol. 135(2), 153-158 (2011).
33. Alexiou Ch, Hulin P, Klein RJ, Bergemann Ch, Arnold W. Magnetic drug targeting: biodistribution and dependency on magnetic field strength. J. Magn. Magn. Mater. 252, 363-366 (2002).
34. Alexiou C, Schmid RJ, Jurgons R et al. Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur. Biophys. J. Biophys. Lett. 35(5), 446-450 (2006).
35. Tietze R, Schreiber E, Lyer S, Alexiou C. Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: A versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UV. J. Biomed. Biotechnol. 2010, 597304 (2010).
36. Alexiou C, Arnold W, Klein RJ et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 60(23), 6641-6648 (2000). First successful treatment of tumor-carrying animals using magnetic drug targeting.
37. Lyer S, Tietze R, Jurgons R et al. Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles - a pilot study. Anticancer Res. 30(5), 1553-1557 (2010).
38. Plank C, Scherer F, Schillinger U, Bergemann C, Anton M. Magnetofection: enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields. J. Liposome Res. 13(1), 29-32 (2003).
39. Huttinger C, Hirschberger J, Jahnke A et al. Neoadjuvant gene delivery of feline granulocyte-macrophage colony-stimulating factor using magnetofection for the treatment of feline fibrosarcomas: A Phase I trial. J. Gene Med. 10(6), 655-667 (2008).
40. Laurent N, Sapet C, Le Gourrierec L, Bertosio E, Zelphati O. Nucleic acid delivery using magnetic nanoparticles: the Magnetofection™ technology. Therapeutic Deliv. 2(4), 471-482 (2011).
41. Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med. Scand. Suppl. 276, 1-103 (1953).
42. Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrott JC, Taylor CB. Selective inductive heating of lymph nodes. Ann. Surg. 146(4), 596-606 (1957).
43. Gordon RT, Hines JR, Gordon D. Intracellular hyperthermia. A biophysical approach to cancer treatment via intracellular temperature and biophysical alterations. Med. Hypotheses 5(1), 83-102 (1979).
44. Jordan A, Scholz R, Wust P et al. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Intern. J. Hyperthermia 13(6), 587-605 (1997).
45. Johannsen M, Thiesen B, Jordan A et al. Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. Prostate 64(3), 283-292 (2005).
46. Hilger I, Andra W, Hergt R, Hiergeist R, Schubert H, Kaiser WA. Electromagnetic heating of breast tumors in interventional radiology: in vitro and in vivo studies in human cadavers and mice. Radiology 218(2), 570-575 (2001).
47. Moskovitz B, Meyer G, Kravtzov A et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann. Oncol. 16(4), 585-589 (2005).
48. Arap W, Haedicke W, Bernasconi M et al. Targeting the prostate for destruction through a vascular address. Proc. Natl Acad. Sci. USA 99(3), 1527-1531 (2002).
49. Torchilin VP. Drug targeting. Eur. J. Pharm. Sci. 11, S81-S91 (2000).
50. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31, 288-299 (1986).
51. Shen Z, Wei W, Zhao YJ et al. Thermosensitive polymer-conjugated albumin nanospheres as thermal targeting anti-cancer drug carrier. Eur. J. Pharm. Sci. 35(4), 271-282 (2008).
52. Chuang CY, Don TM, Chiu WY. Synthesis of chitosan-based thermo- and pH-responsive porous nanoparticles by temperature-dependent self-assembly method and their application in drug release. J. Polymer Sci. A Polymer Chem. 47(19), 5126-5136 (2009).
53. Chiu WY, Chuang CY, Don TM. Synthesis and properties of chitosan-based thermo- and pH-responsive nanoparticles and application in drug release. J. Polymer Sci. A Polymer Chem. 47(11), 2798-2810 (2009).
54. Stover TC, Kim YS, Lowe TL, Kester M. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials 29(3), 359-369 (2008).
55. Gates BD, Bakhtiari ABS, Hsiao D, Jin GX, Branda NR. An efficient method based on the photothermal effect for the release of molecules from metal nanoparticle surfaces. Angew. Chem. Int. Ed. Engl. 48(23), 4166-4169 (2009). Very sophisticated drug release concept that promises a controlled release for therapeutics affected by external triggers.
56. Purushotham S, Chang PE, Rumpel H et al. Thermoresponsive core-shell magnetic nanoparticles for combined modalities of cancer therapy. Nanotechnology 20(30), 305101-305112 (2009).
57. Nacev A, Beni C, Bruno O, Shapiro B. Magnetic nanoparticle transport within flowing blood and into surrounding tissue. Nanomedicine 5(9), 1459-1466 (2010). One of the first well-founded investigations on magnetic nanoparticles in physiological media that gives information for future clinical applicants.
58. Nacev A, Beni C, Bruno O, Shapiro B. The behaviors of ferromagnetic nano-particles in and around blood vessels under applied magnetic fields. J. Magn. Magn. Mater. 323(6), 651-668 (2011).
59. Monopoli MP, Bombelli FB, Dawson KA. Nanobiotechnology: Nanoparticle coronas take shape. Nat. Nanotechnol. 6(1), 11-12 (2011).
60. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. Nanotechnology and aptamers: Applications in drug delivery. Trends Biotechnol. 26(8), 442-449 (2008).
61. Welch MJ, Hawker CJ, Wooley KL. The advantages of nanoparticles for PET. J. Nucl. Med. 50(11), 1743-1746 (2009).
62. Drexler E. Engines of Creation: the Coming Era of Nanotechnology in 1986. Anchor Books, CA, USA (1986).
63. Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. BMJ 331(7517), 614-617 (2005).
64. Gatenby RA. A change of strategy in the war on cancer. Nature 459, 508-509 (2009).
65. Gleich B, Weizenecker R. Tomographic imaging using the nonlinear response of magnetic particles. Nature 435(7046), 1214-1217 (2005).
66. Yang X, Hong H, Grailer JJ et al. cRGD-functionalized, DOX-conjugated, and Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 32(17), 4151-4160 (2011).
67. Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Acc. Chem. Res. 44(10), 875-882 (2011).
68. Levy M, Quarta A, Espinosa A et al. Correlating magneto-structural properties to hyperthermia performance of highly monodisperse iron oxide nanoparticles prepared by a seeded-growth route. Chem. Mater. 23(18), 4170-4180 (2011).
69. Lartigue L, Innocenti C, Kalaivani T et al. Water-dispersible sugar-coated iron oxide nanoparticles. an evaluation of their relaxometric and magnetic hyperthermia properties. J. Am. Chem. Soc. 133(27), 10459-10472 (2011).
70. Chandrasekharan P, Maity D, Yong CX, Chuang KH, Ding J, Feng SS. Vitamin E (d-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials 32(24), 5663-5672 (2011).
71. Mohammad F, Balaji G, Weber A, Uppu RM, Kumar CS. Influence of gold nanoshell on hyperthermia of super paramagnetic iron oxide nanoparticles (SPIONs). J. Phys. Chem. C Nanomater Interfaces 1(20), 3141-3146 (2010).
72. Nigam S, Barick KC, Bahadur D. Development of citrate-stabilized Fe3O4 nanoparticles: conjugation and release of doxorubicin for therapeutic applications. J. Magn. Magn. Mater. 323(2), 237-243 (2011).
73. Zhang GD, Liao YF, Baker I. Surface engineering of core/shell iron/iron oxide nanoparticles from microemulsions for hyperthermia. Mat. Sci. Eng. C Mater. 30(1), 92-97 (2010).
74. Thomas LA, Dekker L, Kallumadil M et al. Carboxylic acid-stabilised iron oxide nanoparticles for use in magnetic hyperthermia. J. Mater. Chem. 19(36), 6529-6535 (2009).
75. Cengelli F, Grzyb JA, Montoro A, Hofmann H, Hanessian S, Juillerat-Jeanneret L. Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin. ChemMedChem 4(6), 988-997 (2009).
76. Gaihre B, Aryal S, Barakat NaM, Kim HY. Gelatin stabilized iron oxide nanoparticles as a three dimensional template for the hydroxyapatite crystal nucleation and growth. Mat. Sci. Eng. C Bio. S 28(8), 1297-1303 (2008).
77. Sun C, Fang C, Stephen Z et al. Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine (Lond.) 3(4), 495-505 (2008).
78. Yu MK, Jeong YY, Park J et al. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew. Chem. Int. Ed. 47(29), 5362-5365 (2008).
79. Drake P, Cho HJ, Shih PS et al.Gd-doped iron-oxide nanoparticles for tumour therapy via magnetic field hyperthermia. J. Mater. Chem. 17(46), 4914-4918 (2007).
80. Zeng Q, Baker I, Loudis JA, Liao Y, Hoopes PJ, Weaver JB. Fe/Fe oxide nanocomposite particles with large specific absorption rate for hyperthermia. Appl. Phys. Lett. 90(23), 233112 (2007).
81. Rodrigues MMA, Simioni AR, Primo FL, Siqueira-Moura MP, Morais PC, Tedesco AC. Preparation, characterization and in vitro cytotoxicity of BSA-based nanospheres containing nanosized magnetic particles and/or photosensitizer. J. Magn. Magn. Mater. 321(10), 1600-1603 (2009).
82. Gonzales-Weimuller M, Zeisberger M, Krishnan KM. Size-dependant heating rates of iron oxide nanoparticles for magnetic fluid hyperthermia. J. Magn. Magn. Mater. 321(13), 1947-1950 (2009).